A detailed history of Ares Financial Consulting, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Ares Financial Consulting, LLC holds 25 shares of BIIB stock, worth $4,188. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25
Holding current value
$4,188
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 29, 2026

BUY
$142.26 - $167.55 $3,556 - $4,188
25 New
25 $4.4 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $24.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Ares Financial Consulting, LLC Portfolio

Follow Ares Financial Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ares Financial Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ares Financial Consulting, LLC with notifications on news.